Literature DB >> 27667579

IBS and IBD - separate entities or on a spectrum?

Robin Spiller1, Giles Major1.   

Abstract

The acute phase of IBD with inflamed gut and often ulcerated mucosa is clearly different from the apparently normal mucosa characteristic of IBS. However, more detailed assessment has detected immune activation, increased gut permeability, increased mucosal serotonin availability, abnormalities of enteric nerve structure and function, and dysbiosis in gut microbiota in IBS - all features seen in IBD. Furthermore, as treatments for inflammation in IBD have become more effective it is now apparent that ∼1 in 3 patients with IBD in remission from inflammation still have persistent abnormalities of sensation, motility and gut microbiota, which might cause IBS-like symptoms. This Perspective explores the overlap between IBS and IBD and their treatments, proposing future directions for research in this stimulating area.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27667579     DOI: 10.1038/nrgastro.2016.141

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  133 in total

1.  Different intestinal permeability patterns in relatives and spouses of patients with Crohn's disease: an inherited defect in mucosal defence?

Authors:  J D Söderholm; G Olaison; E Lindberg; U Hannestad; A Vindels; C Tysk; G Järnerot; R Sjödahl
Journal:  Gut       Date:  1999-01       Impact factor: 23.059

Review 2.  Genetics and pathogenesis of inflammatory bowel disease.

Authors:  Bernard Khor; Agnès Gardet; Ramnik J Xavier
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

3.  Brain responses to visceral stimuli reflect visceral sensitivity thresholds in patients with irritable bowel syndrome.

Authors:  Mats B O Larsson; Kirsten Tillisch; A D Craig; Maria Engström; Jennifer Labus; Bruce Naliboff; Peter Lundberg; Magnus Ström; Emeran A Mayer; Susanna A Walter
Journal:  Gastroenterology       Date:  2011-11-19       Impact factor: 22.682

4.  The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome.

Authors:  Philip M Brown; Douglas A Drossman; Alastair J J Wood; Gary A Cline; Kenny S Frazier; Jessica I Jackson; Johanna Bronner; Joel Freiman; Brian Zambrowicz; Arthur Sands; Michael D Gershon
Journal:  Gastroenterology       Date:  2011-05-18       Impact factor: 22.682

5.  Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms.

Authors:  Cesare Cremon; Luciana Gargano; Antonio M Morselli-Labate; Donatella Santini; Rosanna F Cogliandro; Roberto De Giorgio; Vincenzo Stanghellini; Roberto Corinaldesi; Giovanni Barbara
Journal:  Am J Gastroenterol       Date:  2009-01-13       Impact factor: 10.864

6.  Prognosis in post-infective irritable bowel syndrome: a six year follow up study.

Authors:  K R Neal; L Barker; R C Spiller
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

7.  Concentration-dependent stimulation of intestinal phase III of migrating motor complex by circulating serotonin in humans.

Authors:  M Lördal; H Wallén; P Hjemdahl; O Beck; P M Hellström
Journal:  Clin Sci (Lond)       Date:  1998-06       Impact factor: 6.124

8.  Luminally released serotonin stimulates colonic motility and accelerates colonic transit in rats.

Authors:  Kiyoshi Tsukamoto; Hajime Ariga; Chris Mantyh; Theodore N Pappas; Hidenori Yanagi; Takehira Yamamura; Toku Takahashi
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2007-04-18       Impact factor: 3.619

9.  Infectious gastroenteritis and risk of developing inflammatory bowel disease.

Authors:  Chad K Porter; David R Tribble; Pablo A Aliaga; Heather A Halvorson; Mark S Riddle
Journal:  Gastroenterology       Date:  2008-06-05       Impact factor: 22.682

Review 10.  Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis.

Authors:  A C Ford; N J Talley; P S Schoenfeld; E M M Quigley; P Moayyedi
Journal:  Gut       Date:  2008-11-10       Impact factor: 23.059

View more
  50 in total

1.  High-Fat Diet and Antibiotics Cooperatively Impair Mitochondrial Bioenergetics to Trigger Dysbiosis that Exacerbates Pre-inflammatory Bowel Disease.

Authors:  Jee-Yon Lee; Stephanie A Cevallos; Mariana X Byndloss; Connor R Tiffany; Erin E Olsan; Brian P Butler; Briana M Young; Andrew W L Rogers; Henry Nguyen; Kyongchol Kim; Sang-Woon Choi; Eunsoo Bae; Je Hee Lee; Ui-Gi Min; Duk-Chul Lee; Andreas J Bäumler
Journal:  Cell Host Microbe       Date:  2020-07-14       Impact factor: 21.023

2.  The serotonin receptor 3E variant is a risk factor for female IBS-D.

Authors:  Nikola Fritz; Sabrina Berens; Yuanjun Dong; Cristina Martínez; Stefanie Schmitteckert; Lesley A Houghton; Miriam Goebel-Stengel; Verena Wahl; Maria Kabisch; Dorothea Götze; Mauro D'Amato; Tenghao Zheng; Ralph Röth; Hubert Mönnikes; Jonas Tesarz; Felicitas Engel; Annika Gauss; Martin Raithel; Viola Andresen; Jutta Keller; Thomas Frieling; Christian Pehl; Christoph Stein-Thöringer; Gerard Clarke; Paul J Kennedy; John F Cryan; Timothy G Dinan; Eamonn M M Quigley; Robin Spiller; Caroll Beltrán; Ana María Madrid; Verónica Torres; Emeran A Mayer; Gregory Sayuk; Maria Gazouli; George Karamanolis; Mariona Bustamante; Xavier Estivil; Raquel Rabionet; Per Hoffmann; Markus M Nöthen; Stefanie Heilmann-Heimbach; Börge Schmidt; André Franke; Wolfgang Lieb; Wolfgang Herzog; Guy Boeckxstaens; Mira M Wouters; Magnus Simrén; Gudrun A Rappold; Maria Vicario; Javier Santos; Rainer Schaefert; Justo Lorenzo-Bermejo; Beate Niesler
Journal:  J Mol Med (Berl)       Date:  2022-09-19       Impact factor: 5.606

3.  Chronic psychological stress alters gene expression in rat colon epithelial cells promoting chromatin remodeling, barrier dysfunction and inflammation.

Authors:  John W Wiley; Gerald A Higgins; Shuangsong Hong
Journal:  PeerJ       Date:  2022-04-29       Impact factor: 3.061

4.  Global Research Trends in Irritable Bowel Syndrome: A Bibliometric and Visualized Study.

Authors:  Tai Zhang; Xiangxue Ma; Wende Tian; Jiaqi Zhang; Yuchen Wei; Beihua Zhang; Fengyun Wang; Xudong Tang
Journal:  Front Med (Lausanne)       Date:  2022-06-27

Review 5.  Abnormal gut motility in inflammatory bowel disease: an update.

Authors:  G Bassotti; E Antonelli; V Villanacci; R Nascimbeni; M P Dore; G M Pes; G Maconi
Journal:  Tech Coloproctol       Date:  2020-02-15       Impact factor: 3.781

6.  The 5-HT3 Receptor Affects Rotavirus-Induced Motility.

Authors:  Marie Hagbom; Arash Hellysaz; Claudia Istrate; Johan Nordgren; Sumit Sharma; Felipe Meira de-Faria; Karl-Eric Magnusson; Lennart Svensson
Journal:  J Virol       Date:  2021-07-12       Impact factor: 5.103

7.  miR-16 and miR-103 impact 5-HT4 receptor signalling and correlate with symptom profile in irritable bowel syndrome.

Authors:  Carolin Wohlfarth; Stefanie Schmitteckert; Janina D Härtle; Lesley A Houghton; Harsh Dweep; Marina Fortea; Ghazaleh Assadi; Alexander Braun; Tanja Mederer; Sarina Pöhner; Philip P Becker; Christine Fischer; Martin Granzow; Hubert Mönnikes; Emeran A Mayer; Gregory Sayuk; Guy Boeckxstaens; Mira M Wouters; Magnus Simrén; Greger Lindberg; Bodil Ohlsson; Peter Thelin Schmidt; Aldona Dlugosz; Lars Agreus; Anna Andreasson; Mauro D'Amato; Barbara Burwinkel; Justo Lorenzo Bermejo; Ralph Röth; Felix Lasitschka; Maria Vicario; Marco Metzger; Javier Santos; Gudrun A Rappold; Cristina Martinez; Beate Niesler
Journal:  Sci Rep       Date:  2017-10-31       Impact factor: 4.379

Review 8.  Noninvasive vagal nerve stimulation for gastroenterology pain disorders.

Authors:  Andres Gottfried-Blackmore; Aida Habtezion; Linda Nguyen
Journal:  Pain Manag       Date:  2020-10-28

9.  Acute visceral pain relief mediated by A3AR agonists in rats: involvement of N-type voltage-gated calcium channels.

Authors:  Elena Lucarini; Elisabetta Coppi; Laura Micheli; Carmen Parisio; Alessia Vona; Federica Cherchi; Anna M Pugliese; Felicita Pedata; Paola Failli; Seph Palomino; Jared Wahl; Tally M Largent-Milnes; Todd W Vanderah; Dilip K Tosh; Kenneth A Jacobson; Daniela Salvemini; Carla Ghelardini; Lorenzo Di Cesare Mannelli
Journal:  Pain       Date:  2020-09-01       Impact factor: 7.926

10.  The alternative serotonin transporter promoter P2 impacts gene function in females with irritable bowel syndrome.

Authors:  Sandra Mohr; Nikola Fritz; Christian Hammer; Cristina Martínez; Sabrina Berens; Stefanie Schmitteckert; Verena Wahl; Malin Schmidt; Lesley A Houghton; Miriam Goebel-Stengel; Maria Kabisch; Dorothea Götze; Irina Milovač; Mauro D'Amato; Tenghao Zheng; Ralph Röth; Hubert Mönnikes; Felicitas Engel; Annika Gauss; Jonas Tesarz; Martin Raithel; Viola Andresen; Thomas Frieling; Jutta Keller; Christian Pehl; Christoph Stein-Thöringer; Gerard Clarke; Paul J Kennedy; John F Cryan; Timothy G Dinan; Eamonn M M Quigley; Robin Spiller; Caroll Beltrán; Ana María Madrid; Verónica Torres; Edith Pérez de Arce; Wolfgang Herzog; Emeran A Mayer; Gregory Sayuk; Maria Gazouli; George Karamanolis; Lejla Kapur-Pojskič; Mariona Bustamante; Raquel Rabionet; Xavier Estivil; André Franke; Wolfgang Lieb; Guy Boeckxstaens; Mira M Wouters; Magnus Simrén; Gudrun A Rappold; Maria Vicario; Javier Santos; Rainer Schaefert; Justo Lorenzo-Bermejo; Beate Niesler
Journal:  J Cell Mol Med       Date:  2021-06-24       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.